Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02648347




Registration number
NCT02648347
Ethics application status
Date submitted
4/01/2016
Date registered
7/01/2016
Date last updated
27/06/2022

Titles & IDs
Public title
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
Scientific title
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)
Secondary ID [1] 0 0
2015-004265-81
Secondary ID [2] 0 0
AKB-6548-CI-0014
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anemia 0 0
Non-Dialysis-Dependent Chronic Kidney Disease 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vadadustat
Treatment: Drugs - Darbepoetin alfa

Experimental: Vadadustat -

Active comparator: Darbepoetin alfa -


Treatment: Drugs: Vadadustat
Oral dose administered once daily for =36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Treatment: Drugs: Darbepoetin alfa
Subcutaneous or intravenous dose administered for =36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)
Timepoint [1] 0 0
Baseline; Weeks 24 to 36
Primary outcome [2] 0 0
Median Time to First Major Adverse Cardiovascular Event (MACE)
Timepoint [2] 0 0
Up to Week 208
Secondary outcome [1] 0 0
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)
Timepoint [1] 0 0
Baseline; Weeks 40 to 52
Secondary outcome [2] 0 0
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis
Timepoint [2] 0 0
Up to Week 208
Secondary outcome [3] 0 0
Median Time to First Cardiovascular MACE
Timepoint [3] 0 0
Up to Week 208
Secondary outcome [4] 0 0
Median Time to First Cardiovascular Death
Timepoint [4] 0 0
Up to Week 208
Secondary outcome [5] 0 0
Median Time to First All-cause Mortality
Timepoint [5] 0 0
Up to Week 208

Eligibility
Key inclusion criteria
* =18 years of age
* Diagnosis of chronic kidney disease (CKD) with an estimated glomerular filtration rate =60 milliliters per minute per 1.73 square meter (mL/min/1.73 m^2) at Screening and not expected to start dialysis within 6 months of Screening
* Mean Screening hemoglobin <10.0 grams per deciliter (g/dL)
* Serum ferritin =100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) =20% during Screening
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Anemia due to a cause other than CKD or participants with active bleeding or recent blood loss
* Red blood cell transfusion within 8 weeks prior to randomization.
* Any erythropoietic stimulating agent within 8 weeks prior to randomization
* Uncontrolled hypertension
* Severe heart failure at Screening (New York Heart Association Class IV)
* Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure, or stroke within 12 weeks prior to or during Screening
* Hypersensitivity to Darbepoetin or Vadadustat or to any of their excipients

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
31/07/2020
Sample size
Target
Accrual to date
Final
1751
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Liverpool
Recruitment hospital [3] 0 0
Research Site - Cairns
Recruitment hospital [4] 0 0
Research Site - Gold Coast
Recruitment hospital [5] 0 0
Research Site - Herston
Recruitment hospital [6] 0 0
Research Site - Adelaide
Recruitment hospital [7] 0 0
Research Site - Bedford Park
Recruitment hospital [8] 0 0
Research Site - Box Hill
Recruitment hospital [9] 0 0
Research Site - Nedlands
Recruitment hospital [10] 0 0
Research Site - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
4870 - Cairns
Recruitment postcode(s) [4] 0 0
9726 - Gold Coast
Recruitment postcode(s) [5] 0 0
4006 - Herston
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
5042 - Bedford Park
Recruitment postcode(s) [8] 0 0
3128 - Box Hill
Recruitment postcode(s) [9] 0 0
6009 - Nedlands
Recruitment postcode(s) [10] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maine
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Mississippi
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
Montana
Country [20] 0 0
United States of America
State/province [20] 0 0
Nebraska
Country [21] 0 0
United States of America
State/province [21] 0 0
Nevada
Country [22] 0 0
United States of America
State/province [22] 0 0
New Hampshire
Country [23] 0 0
United States of America
State/province [23] 0 0
New Jersey
Country [24] 0 0
United States of America
State/province [24] 0 0
New Mexico
Country [25] 0 0
United States of America
State/province [25] 0 0
New York
Country [26] 0 0
United States of America
State/province [26] 0 0
North Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oregon
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
Rhode Island
Country [31] 0 0
United States of America
State/province [31] 0 0
South Carolina
Country [32] 0 0
United States of America
State/province [32] 0 0
Tennessee
Country [33] 0 0
United States of America
State/province [33] 0 0
Texas
Country [34] 0 0
United States of America
State/province [34] 0 0
Utah
Country [35] 0 0
United States of America
State/province [35] 0 0
Virginia
Country [36] 0 0
United States of America
State/province [36] 0 0
Washington
Country [37] 0 0
United States of America
State/province [37] 0 0
Wisconsin
Country [38] 0 0
Argentina
State/province [38] 0 0
Buenos Aires
Country [39] 0 0
Argentina
State/province [39] 0 0
Mendoza
Country [40] 0 0
Argentina
State/province [40] 0 0
Santa Fe
Country [41] 0 0
Argentina
State/province [41] 0 0
Tucuman
Country [42] 0 0
Argentina
State/province [42] 0 0
Ciudad Autonoma Buenos Aires
Country [43] 0 0
Argentina
State/province [43] 0 0
Cordoba
Country [44] 0 0
Argentina
State/province [44] 0 0
Corrientes
Country [45] 0 0
Argentina
State/province [45] 0 0
Salta
Country [46] 0 0
Argentina
State/province [46] 0 0
San Luis
Country [47] 0 0
Brazil
State/province [47] 0 0
Bahia
Country [48] 0 0
Brazil
State/province [48] 0 0
Ceará
Country [49] 0 0
Brazil
State/province [49] 0 0
Espírito Santo
Country [50] 0 0
Brazil
State/province [50] 0 0
Minas Gerais
Country [51] 0 0
Brazil
State/province [51] 0 0
Paraná
Country [52] 0 0
Brazil
State/province [52] 0 0
Rio Do Janeiro
Country [53] 0 0
Brazil
State/province [53] 0 0
Rio Grande Do Sul
Country [54] 0 0
Brazil
State/province [54] 0 0
Santa Catarina
Country [55] 0 0
Brazil
State/province [55] 0 0
Sao Paulo
Country [56] 0 0
Bulgaria
State/province [56] 0 0
Dobrich
Country [57] 0 0
Bulgaria
State/province [57] 0 0
Lom
Country [58] 0 0
Bulgaria
State/province [58] 0 0
Silistra
Country [59] 0 0
Bulgaria
State/province [59] 0 0
Sliven
Country [60] 0 0
Bulgaria
State/province [60] 0 0
Smolyan
Country [61] 0 0
Bulgaria
State/province [61] 0 0
Sofia
Country [62] 0 0
Bulgaria
State/province [62] 0 0
Stara Zagora
Country [63] 0 0
Bulgaria
State/province [63] 0 0
Varna
Country [64] 0 0
Bulgaria
State/province [64] 0 0
Veliko Tarnovo
Country [65] 0 0
Bulgaria
State/province [65] 0 0
Vidin
Country [66] 0 0
France
State/province [66] 0 0
Val d'Oise
Country [67] 0 0
Hungary
State/province [67] 0 0
Baja
Country [68] 0 0
Hungary
State/province [68] 0 0
Balatonfured
Country [69] 0 0
Hungary
State/province [69] 0 0
Budapest
Country [70] 0 0
Hungary
State/province [70] 0 0
Debrecen
Country [71] 0 0
Hungary
State/province [71] 0 0
Hodmezovasarhely
Country [72] 0 0
Hungary
State/province [72] 0 0
Kalocsa
Country [73] 0 0
Hungary
State/province [73] 0 0
Kaposvar
Country [74] 0 0
Hungary
State/province [74] 0 0
Kecskemet
Country [75] 0 0
Hungary
State/province [75] 0 0
Kistarcsa
Country [76] 0 0
Hungary
State/province [76] 0 0
Nyiregyhaza
Country [77] 0 0
Hungary
State/province [77] 0 0
Pecs
Country [78] 0 0
Hungary
State/province [78] 0 0
Szeged
Country [79] 0 0
Hungary
State/province [79] 0 0
Szigetvar
Country [80] 0 0
Israel
State/province [80] 0 0
Ashkelon
Country [81] 0 0
Israel
State/province [81] 0 0
Haifa
Country [82] 0 0
Israel
State/province [82] 0 0
Nahariya
Country [83] 0 0
Israel
State/province [83] 0 0
Ramat Gan
Country [84] 0 0
Israel
State/province [84] 0 0
Rishon Lezion
Country [85] 0 0
Italy
State/province [85] 0 0
Caserta
Country [86] 0 0
Italy
State/province [86] 0 0
Foggia
Country [87] 0 0
Italy
State/province [87] 0 0
Bari
Country [88] 0 0
Italy
State/province [88] 0 0
Bergamo
Country [89] 0 0
Italy
State/province [89] 0 0
Cremona
Country [90] 0 0
Italy
State/province [90] 0 0
Genova
Country [91] 0 0
Italy
State/province [91] 0 0
Lecco
Country [92] 0 0
Italy
State/province [92] 0 0
Milano
Country [93] 0 0
Italy
State/province [93] 0 0
Napoli
Country [94] 0 0
Italy
State/province [94] 0 0
Parma
Country [95] 0 0
Italy
State/province [95] 0 0
Pavia
Country [96] 0 0
Italy
State/province [96] 0 0
Roma
Country [97] 0 0
Italy
State/province [97] 0 0
Siena
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Gyeonggi-do
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Busan
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Daegu
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Seoul
Country [102] 0 0
Malaysia
State/province [102] 0 0
Kelantan
Country [103] 0 0
Malaysia
State/province [103] 0 0
Pahang
Country [104] 0 0
Mexico
State/province [104] 0 0
Distrito Federal
Country [105] 0 0
Mexico
State/province [105] 0 0
Guerrero
Country [106] 0 0
Mexico
State/province [106] 0 0
Hidalgo
Country [107] 0 0
Mexico
State/province [107] 0 0
Jalisco
Country [108] 0 0
Mexico
State/province [108] 0 0
Michoacán
Country [109] 0 0
Mexico
State/province [109] 0 0
Nuevo León
Country [110] 0 0
Mexico
State/province [110] 0 0
Queretaro
Country [111] 0 0
Mexico
State/province [111] 0 0
Sinaloa
Country [112] 0 0
Mexico
State/province [112] 0 0
Chihuahua
Country [113] 0 0
Mexico
State/province [113] 0 0
Durango
Country [114] 0 0
Mexico
State/province [114] 0 0
Veracruz
Country [115] 0 0
New Zealand
State/province [115] 0 0
Hamilton
Country [116] 0 0
New Zealand
State/province [116] 0 0
New Plymouth
Country [117] 0 0
Poland
State/province [117] 0 0
Lodz
Country [118] 0 0
Poland
State/province [118] 0 0
Nowa Sol
Country [119] 0 0
Poland
State/province [119] 0 0
Warszawa
Country [120] 0 0
Poland
State/province [120] 0 0
Wroclaw
Country [121] 0 0
Puerto Rico
State/province [121] 0 0
Caguas
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Kazan
Country [123] 0 0
Russian Federation
State/province [123] 0 0
Kemerovo
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Krasnoyarsk
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Moscow
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Nizhniy Novgorod
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Novosibirsk
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Petrozavodsk
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Pushkin
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Saint-Petersburg
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Tomsk
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Tosno
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Yaroslavl
Country [134] 0 0
South Africa
State/province [134] 0 0
Eastern Cape
Country [135] 0 0
South Africa
State/province [135] 0 0
Free State
Country [136] 0 0
South Africa
State/province [136] 0 0
Gauteng
Country [137] 0 0
South Africa
State/province [137] 0 0
KwaZulu-Natal
Country [138] 0 0
South Africa
State/province [138] 0 0
Western Cape
Country [139] 0 0
Spain
State/province [139] 0 0
Alicante
Country [140] 0 0
Spain
State/province [140] 0 0
Baleares
Country [141] 0 0
Spain
State/province [141] 0 0
Barcelona
Country [142] 0 0
Spain
State/province [142] 0 0
Málaga
Country [143] 0 0
Spain
State/province [143] 0 0
Almeria
Country [144] 0 0
Spain
State/province [144] 0 0
Badajoz
Country [145] 0 0
Spain
State/province [145] 0 0
Madrid
Country [146] 0 0
Spain
State/province [146] 0 0
Sevilla
Country [147] 0 0
Spain
State/province [147] 0 0
Valencia
Country [148] 0 0
Ukraine
State/province [148] 0 0
Dnipro
Country [149] 0 0
Ukraine
State/province [149] 0 0
Ivano-Frankivsk
Country [150] 0 0
Ukraine
State/province [150] 0 0
Kharkiv
Country [151] 0 0
Ukraine
State/province [151] 0 0
Kropyvnytskyi
Country [152] 0 0
Ukraine
State/province [152] 0 0
Kyiv
Country [153] 0 0
Ukraine
State/province [153] 0 0
Lviv
Country [154] 0 0
Ukraine
State/province [154] 0 0
Mykolaiv
Country [155] 0 0
Ukraine
State/province [155] 0 0
Odesa
Country [156] 0 0
Ukraine
State/province [156] 0 0
Vinnytsia
Country [157] 0 0
Ukraine
State/province [157] 0 0
Zaporizhzhia
Country [158] 0 0
Ukraine
State/province [158] 0 0
Zhytomyr
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Grampian Region
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Greater London
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Greater Manchester
Country [162] 0 0
United Kingdom
State/province [162] 0 0
Hertfordshire
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Leicestershire
Country [164] 0 0
United Kingdom
State/province [164] 0 0
South Yorkshire
Country [165] 0 0
United Kingdom
State/province [165] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Akebia Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
Trial website
https://clinicaltrials.gov/study/NCT02648347
Trial related presentations / publications
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, Block GA, Burke S, Castillo FP, Jardine AG, Khawaja Z, Koury MJ, Lewis EF, Lin T, Luo W, Maroni BJ, Matsushita K, McCullough PA, Parfrey PS, Roy-Chaudhury P, Sarnak MJ, Sharma A, Spinowitz B, Tseng C, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Eckardt KU; PRO2TECT Study Group. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 Apr 29;384(17):1589-1600. doi: 10.1056/NEJMoa2035938.
Public notes

Contacts
Principal investigator
Name 0 0
Chief Medical Officer
Address 0 0
Akebia Therapeutics Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02648347